Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Kristen E. Pascal
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans - Nature
Correction to: Nature https://doi.org/10.1038/s41586-021-03653-6 Published online 27 May 2021 In this article, we reported that some participants exhibited pre-existing CD4+ and CD8+ T-cell responses against the C-terminal part of the SARS-CoV-2 spike protein.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
Highlights • REGEN-COV retains neutralization potency against current variants of concern/interest • In vitro escape studies can predict emergence of viral variants in animals and humans • 3 noncompeting mAb in combination reduce variant risk compared to a combination of 2. • Treatment with REGEN-COV in humans does not lead to emergence of viral variants Summary Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19.
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Highlights • The SARS-CoV-2 D614G S protein variant supplanted the ancestral virus in people • D614G increases infectivity on human lung cells or cells with bat or pangolin ACE2 • D614G is potently neutralized by antibodies targeting the receptor-binding domain • D614G shifts S protein conformation toward an ACE2-binding fusion-competent state Summary The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral virus worldwide, reaching near fixation in a matter of months.
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Highlights • The SARS-CoV-2 D614G S protein variant supplanted the ancestral virus in people • D614G increases infectivity on human lung cells or cells with bat or pangolin ACE2 • D614G is potently neutralized by antibodies targeting the receptor binding domain • D614G shifts S protein conformation towards an ACE2-binding fusion-competent state Summary The SARS-CoV-2 spike (S) protein variant D614G supplanted the ancestral virus worldwide, reaching near fixation in a matter of months.
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
An antibody cocktail against SARS-CoV-2 There is an urgent focus on antibodies that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral spike and prevent the virus from entering host cells. Hansen et al. generated a large panel of antibodies against the spike protein from humanized mice and recovered patients. From this panel, they identified several neutralizing antibodies, including pairs that do not compete for binding to the receptor binding domain. Baum et al.
SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Abstract Neutralizing antibodies have become an important tool in treating infectious diseases. Recently, two separate approaches yielded successful antibody treatments for Ebola – one from genetically-humanized mice, and the other from a human survivor.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Kristen E.
Contact Kristen E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack